New Jersey drugmaker files for bankruptcy

Melinta Therapeutics, an antibiotics maker based in Morristown, N.J., filed for Chapter 11 bankruptcy Dec. 27.

The drugmaker has reached a debt-for-equity exchange with healthcare investment firm Deerfield Management Co. 

Under the agreement, the investment firm will acquire the company and wipe out $140 million in debt.

In the bankruptcy petition, Melinta listed about $500 million in assets and up to $500 million in liabilities, according to Bloomberg.

The drugmaker plans to operate normally through the bankruptcy process. 

The company, founded in 2000, sells drugs that treat methicillin-resistant staphylococcus aureus, urinary tract and other bacterial infections.

More articles on pharmacy:

Drugmakers shift from clinical trials, mine EMRs for drug approvals
Roche buys international rights to Sarepta's Duchenne drug for $750M
Former Aegerion sales rep defrauded insurers, stole identities to push cholesterol drug

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars